- Partnership seeks to improve patient outcomes and experience
through novel digital and diagnostic solutions.
- Investment aligns with Danaher's mission to accelerate the
transition to precision medicine with AI-enabled
diagnostics.
WASHINGTON, Jan. 9, 2025
/PRNewswire/ -- Danaher Diagnostics LLC and Danaher Ventures LLC,
two subsidiaries of Danaher Corporation (NYSE: DHR) ("Danaher"), a
global science and technology innovator, announced today that they
have formed an investment partnership with Innovaccer Inc., a
leading healthcare artificial intelligence (AI) company.
Innovaccer has built a suite of software solutions designed to
create a unified patient record to identify gaps in care and
patients at risk, as well as appropriate interventions to improve
patient outcomes. As part of the investment partnership, Danaher,
along with Innovaccer and its network of healthcare systems, seeks
to accelerate the adoption of precision diagnostics both by
clinicians and population health teams, facilitating value-based
care.
"Patients are at the center of everything we do at Danaher. We
believe our investment partnership with Innovaccer will empower
patients and speed the transition to more personalized, value-based
medicine by providing healthcare providers with the data and
analytics needed to drive meaningful clinical insights, more
quickly, and at the point of need," said Julie Sawyer Montgomery, Executive Vice
President, Danaher Corporation.
"Danaher is committed to ethically using AI to develop and
deliver better diagnostics to help doctors treat their patients
with the right medicine in the right dose at the right time," said
Murali Venkatesan, Head of Danaher
Ventures, Americas & Europe
and Vice President of Science, Technology and Innovation, Danaher
Corporation. "We're excited to connect our innovation ecosystem
with Innovaccer's to enable this healthcare transformation."
"At Innovaccer, we are on a mission to improve health outcomes
through our data platform and AI capabilities," said Abhinav Shashank, cofounder and CEO of
Innovaccer. "We believe that partnering with Danaher will
accelerate our efforts to advance diagnostic and clinical AI
solutions."
ABOUT DANAHER
Danaher is a leading global life
sciences and diagnostics innovator, committed to accelerating the
power of science and technology to improve human health. Our
businesses partner closely with customers to solve many of the most
important health challenges impacting patients around the world.
Danaher's advanced science and technology – and proven ability to
innovate – help enable faster, more accurate diagnoses and help
reduce the time and cost needed to sustainably discover, develop
and deliver life-changing therapies. Focused on scientific
excellence, innovation and continuous improvement, our
approximately 63,000 associates worldwide help ensure that Danaher
is improving quality of life for billions of people today, while
setting the foundation for a healthier, more sustainable tomorrow.
Explore more at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical,
including any statements regarding events or developments that
Danaher believes or anticipates will or may occur in the future are
"forward-looking" statements within the meaning of the federal
securities laws. These factors include, among other things:
unanticipated, further declines in demand for our COVID-19 related
products, the impact of global health crises, the impact of our
debt obligations on our operations and liquidity, deterioration of
or instability in the global economy, the markets we serve and the
financial markets, uncertainties with respect to the development,
deployment, and use of artificial intelligence in our business and
products, uncertainties relating to national laws or policies,
including laws or policies to protect or promote domestic interests
and/or address foreign competition, contractions or growth rates
and cyclicality of markets we serve, competition, our ability to
develop and successfully market new products and technologies and
expand into new markets, the potential for improper conduct by our
employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to
off-label marketing and other regulations relating to medical
devices and the health care industry), the results of our clinical
trials and perceptions thereof, our ability to effectively address
cost reductions and other changes in the health care industry, our
ability to successfully identify and consummate appropriate
acquisitions and strategic investments, our ability to integrate
the businesses we acquire and achieve the anticipated growth,
synergies and other benefits of such acquisitions, contingent
liabilities and other risks relating to acquisitions, investments,
strategic relationships and divestitures (including tax-related and
other contingent liabilities relating to past and future IPOs,
split-offs or spin-offs), security breaches or other disruptions of
our information technology systems or violations of data privacy
laws, the impact of our restructuring activities on our ability to
grow, risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of
the United States government with
respect to our production capacity in times of national emergency
or with respect to intellectual property/production capacity
developed using government funding, risks relating to product,
service or software defects, product liability and recalls, risks
relating to our manufacturing operations and fluctuations in the
cost and availability of the supplies we use (including
commodities) and labor we need for our operations, our
relationships with and the performance of our channel partners,
uncertainties relating to collaboration arrangements with
third-parties, the impact of deregulation on demand for our
products and services, the impact of climate change, legal or
regulatory measures to address climate change and our ability to
address stakeholder expectations relating to climate change, labor
matters and our ability to recruit, retain and motivate talented
employees representing diverse backgrounds, experiences and skill
sets, non-U.S. economic, political, legal, compliance, social and
business factors (including the impact of military conflicts),
disruptions relating to man-made and natural disasters, inflation
and the impact of our By-law exclusive forum provisions. Additional
information regarding the factors that may cause actual results to
differ materially from these forward-looking statements is
available in our SEC filings, including our 2023 Annual Report on
Form 10-K and Quarterly Report on Form 10-Q for the third quarter
of 2024. These forward-looking statements speak only as of the date
of this release and except to the extent required by applicable
law, the Company does not assume any obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events and developments or otherwise.
View original
content:https://www.prnewswire.com/news-releases/danaher-announces-investment-partnership-in-innovaccer-inc-302347452.html
SOURCE Danaher Corporation
